| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Greenwich Lifesciences, Inc. (GLSI) has 1 insider with recent SEC Form 4 filings, including 10 buys and 0 sells. GLSI is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 5.61M | $80.75M | +7.3K |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr 1, 2024 | Patel Snehal61 | CEO And CFO | Buy | 3,000 | $19.08 | $57,240.00 | - | -11.9% | -51.4% | |
| Mar 22, 2024 | Patel Snehal61 | CEO And CFO | Buy | 2,500 | $19.98 | $49,950.00 | - | -22.0% | -43.4% | |
| Mar 20, 2024 | Patel Snehal61 | CEO And CFO | Buy | 1,500 | $17.68 | $26,520.00 | - | -13.1% | -38.3% | |
| Mar 5, 2024 | Patel Snehal61 | CEO And CFO | Buy | 30,500 | $12.49 | $380,945.00 | +0.6% | +11.3% | -4.9% | |
| Mar 4, 2024 | Patel Snehal61 | CEO And CFO | Buy | 4,100 | $13.03 | $53,423.00 | - | +7.9% | -7.8% | |
| Feb 16, 2024 | Patel Snehal61 | CEO And CFO | Buy | 10,800 | $11.16 | $120,528.00 | +0.2% | +28.6% | +10.1% | |
| Feb 15, 2024 | Patel Snehal61 | CEO And CFO | Buy | 12,700 | $11.07 | $140,589.00 | +0.2% | +27.2% | +6.7% | |
| Nov 10, 2023 | Patel Snehal61 | CEO And CFO | Buy | 5,000 | $10.17 | $50,837.50 | - | -16.6% | +41.5% | |
| Nov 3, 2023 | Patel Snehal61 | CEO And CFO | Buy | 3,500 | $9.11 | $31,885.00 | - | -1.8% | +48.5% | |
| Oct 27, 2023 | Thompson Jaye53 | VP Clinical Reg Affairs | Buy | 500 | $8.57 | $4,285.00 | +0.2% | +3.5% | +58.5% |